Crinetics Pharmaceuticals Inc (NAS:CRNX)

$ 46.1 -0.76 (-1.62%) Market Cap: 3.64 Bil Enterprise Value: 2.85 Bil PE Ratio: 0 PB Ratio: 4.14 GF Score: 35/100

Q4 2023 Crinetics Pharmaceuticals Inc Earnings Call Transcript
Feb 28, 2024

$42.76 (+5.66%)

Earnings
Crinetics Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript
Jan 09, 2024
Crinetics Pharmaceuticals Inc Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome Transcript
Dec 18, 2023
Crinetics Pharmaceuticals Inc Data Review Conference Call Transcript
Sep 11, 2023
Crinetics Pharmaceuticals Inc to Host Key Opinion Leader (KOL) Webinar Transcript
Aug 08, 2023
Crinetics Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript
Jan 11, 2023
Crinetics Pharmaceuticals Inc to Discuss CRN04894 Phase 1 Multiple-Ascending Dose Data Call Transcript
May 25, 2022
Crinetics Pharmaceuticals Inc To Discuss Results From MAD Cohorts Of The Phase 1 Trial Of CRN04777 Corporate Call Transcript
Mar 30, 2022
Crinetics Pharmaceuticals Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 12, 2022
Crinetics Pharmaceuticals Inc CRN04777 Phase 1 Program Results Call Transcript
Sep 15, 2021
Crinetics Pharmaceuticals Inc Review CRN04894 Single Ascending Dose Results Call Transcript
Aug 10, 2021
Q4 2020 Crinetics Pharmaceuticals Inc Earnings Call Transcript
Mar 30, 2021

$15.44 (+0.32%)

Earnings
Crinetics Pharmaceuticals Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 13, 2021
Crinetics Pharmaceuticals, Inc. - Special Call Transcript
Nov 20, 2020
Crinetics Pharmaceuticals Inc Review Of Phase 2 Paltusotine Results Call Transcript
Oct 26, 2020
Crinetics Pharmaceuticals, Inc. - Special Call Transcript
Apr 07, 2020
Crinetics Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript
Jan 15, 2020

Crinetics Pharmaceuticals, Inc. - Special Call Transcript

Apr 07, 2020 / 12:00PM GMT

Release Date Price: $13.04 (-10.93%)

Transcript

Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Crinetics Pharmaceuticals ACROBAT EDGE Phase II Interim Results and Corporate Update Conference Call. (Operator Instructions)

I would now like to hand the conference over to your speaker, Robert Uhl. Please go ahead.

Robert H. Uhl

Westwicke Partners, LLC - MD

Thank you, operator. Good morning, everyone, and welcome to Crinetics Pharmaceuticals conference call to provide interim results from the ACROBAT EDGE Phase II clinical trial of once-daily oral paltusotine for the treatment of acromegaly. The company will also provide a corporate update.

Before we begin, I'd like to let you know that on this call, the Crinetics team will reference data that are presented on a set of slides that you can access from the Investor Calendar events page of the Crinetics website. The interim data from the ACROBAT EDGE trial is also contained in the news release from yesterday afternoon. Joining me on the call from Crinetics are Scott Struthers, Founder and Chief Executive Officer; and Alan

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.